Evidence map›Paper›PMID 36387350›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Effects of

Masoumeh Asgharpour, Noora Enayati, Mohammad Rezaei Sadrabadi, Mana Mohamadi Afrakati, Armin Khavandegar, Parham Mardi, Amirhesam Alirezaei, Ali Taherinia, Mahmood Bakhtiyari

Abstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Masoumeh AsgharpourDepartment of Nephrology, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran.
Noora EnayatiDepartment of Phytochemistry, Medicinal Plants and Drug Research Institute, Shahid Beheshti University, Tehran, Iran.
Mohammad Rezaei SadrabadiDepartment of Internal Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mana Mohamadi AfrakatiDepartment of Internal Medicine, Emam Ali Hospital, Alborz University of Medical Sciences, Tehran, Iran.
Armin KhavandegarStudent Research Committee, Alborz University of Medical Sciences, Karaj, Iran.ORCID https://orcid.org/0000-0002-4761-8938
Parham MardiStudent Research Committee, Alborz University of Medical Sciences, Karaj, Iran.
Amirhesam AlirezaeiClinical Research and Development Center, Shahid Modarres Hospital, Department of Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-9720-6723
Ali TaheriniaDepartment of Emergency Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Mahmood BakhtiyariNon-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.ORCID https://orcid.org/0000-0002-1216-7671

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients undergoing hemodialysis (HD) are regularly exposed to oxidative stress and inflammation and may suffer from thirst distress with no definitive treatment to address these complications. Methods: This study was conducted on fifty-three HD patients referred to Tehran Shahid Modarres hospital. The patients were randomly divided into two groups: Group 1 received DS for six weeks, then underwent four weeks of washout period followed by six weeks of placebo treatment, while group 2 received placebo initially followed by treatment with DS. Biochemistry, malondialdehyde (MDA), and total antioxidant capacity (TAC) were measured in four phases: at the beginning, before washout, after washout, and at the end of the study. The patient's body weight was recorded at the start of each session to assess interdialytic weight gain. Thirst scores also were measured using a visual analog scale. Results: A total of 53 patients, including 23 (43.4%) male and 30 (56.6%) female subjects, were included in the study. The results showed a reduction in thirst score ( Conclusion: DS powder-mixed syrup may benefit HD patients by facilitating free radical scavenging and alleviating thirst distress with minimal adverse effects. The seeds could therefore be utilized as a complementary therapy for hemodialysis patients.

Identifiers

PMID36387350
PMCPMC9652079

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.